IDO1 and cancer: All three inhibitors significantly reduced Kyn levels in the cancer cell line supernatants with a fold change (FC) <0.5 versus the control cells (Figure 1A), indicating the efficacy of the IDO1 catalytic inhibitors in all the tested cancer cell lines.